The Spice Sage and Its Active Ingredient Rosmarinic Acid Protect PC12 Cells from Amyloid-β Peptide-Induced Neurotoxicity
- 1 June 2006
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 317 (3) , 1143-1149
- https://doi.org/10.1124/jpet.105.099317
Abstract
Traditional use and clinical reports suggest that the culinary herb sage (Salvia officinalis) may be effective for patients with mild to moderate Alzheimer9s disease (AD). In this study, we evaluated the effect of a standardized extract from the leaves of S. officinalis (SOE) and its active ingredient rosmarinic acid on Alzheimer amyloid-β peptide (Aβ)-induced toxicity in cultured rat pheochromocytoma (PC12) cells. Incubation of PC12 cells with Aβ (fragment 1–42) for 24 h caused cell death, and this effect was reduced by SOE and its active ingredient, rosmarinic acid. Rosmarinic acid reduced a number of events induced by Aβ. These include reactive oxygen species formation, lipid peroxidation, DNA fragmentation, caspase-3 activation, and tau protein hyperphosphorylation. Moreover, rosmarinic acid inhibited phosphorylated p38 mitogen-activated protein kinase but not glycogen synthase kinase 3β activation. These data show the neuroprotective effect of sage against Aβ-induced toxicity, which could validate the traditional use of this spice in the treatment of AD. Rosmarinic acid could contribute, at least in part, for sage-induced neuroprotective effect.Keywords
This publication has 39 references indexed in Scilit:
- Future directions in the treatment of Alzheimer’s diseaseExpert Opinion on Investigational Drugs, 2004
- Absorption, metabolism, degradation and urinary excretion of rosmarinic acid after intake of Perilla frutescens extract in humansEuropean Journal of Nutrition, 2004
- β-Secretase inhibition for the treatment of Alzheimer's disease – promise and challengeTrends in Pharmacological Sciences, 2004
- Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trialJournal of Neurology, Neurosurgery & Psychiatry, 2003
- The Wnt pathway, cell-cycle activation and β-amyloid: novel therapeutic strategies in Alzheimer's disease?Trends in Pharmacological Sciences, 2003
- Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trialJournal of Clinical Pharmacy & Therapeutics, 2003
- Therapeutic Potential in Alzheimer DiseaseCurrent Medicinal Chemistry, 2002
- Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death1Neurobiology of Aging, 2002
- Topical anti-inflammatory activity of Salvia officinalis L. leaves: the relevance of ursolic acidJournal of Ethnopharmacology, 2001
- Lithium protects cultured neurons against β‐amyloid‐induced neurodegenerationFEBS Letters, 1999